| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802023201024 | 202320102 | SEREVENT INH.SOL.P 25 MCG/DOSE ΣΥΣΚΕΥΗ x 120 DOSES (10,2 G) (10,2 G) | 8.30 | 8.71 | 12.00 |
| 05/2018 | 2802023202021 | 202320202 | SEREVENT PD.INH.MD 50MCG/DOSE ΤΑΙΝΙΑx60BLISTERS AL σε πλαστική συσκευή DISCUS AL σε πλαστική συσκευή DISCUS | 14.12 | 14.81 | 20.41 |
For the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Salmeterol's long, lipophilic side chain binds to exosites near beta(2)-receptors in the lungs and on bronchiolar smooth muscle, allowing the active portion of the molecule to remain at the receptor site, continually binding and releasing. Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor. By the oral route, no deaths occurred in rats at 1,000 mg/kg (approximately 81,000 times the maximum recommended daily inhalation dose in adults and approximately 38,000 times the maximum recommended daily inhalation dose in children on a mg/m<sup>2</sup> basis).
Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.
5.5 hours